18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the...

Home / News / Pearce IP Blog
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the...
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that...
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Australian and New Zealand patent examiners typically frown upon the use of trade marks in claims. Primarily, a trade...
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira®...
22 JUN 2023 | JP | ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel...
The Full Federal Court handed down its decision this morning in the longstanding dispute as to whether the...
The PBS listing for Chiesi’s Epidyolex®, an oral cannabidiol, was expanded on 1 June 2023 to include treatment of...